Merck: agreement to acquire Imago BioSciences

(CercleFinance.com) - Merck (MSD outside North America) today announced that it has entered into a definitive agreement to acquire Imago BioSciences for 36 dollars per share, in cash, representing a total value of approximately 1.
35 billion dollars.

The biopharmaceutical company develops new drugs for the treatment of myeloproliferative neoplasms and other bone marrow diseases. Its bomedemstat is currently being evaluated in several Phase 2 clinical trials.

Merck will launch a tender offer, the completion of which will be subject to certain conditions, including the tender of shares representing at least a majority of the total number of Imago shares. The transaction is expected to close in Q1 2023.


Copyright (c) 2022 CercleFinance.com. All rights reserved.